Sean Wharton
Sean Wharton is the director of the Wharton Medical Clinic in Burlington, recognized for his expertise in obesity and diabetes management. He recently expressed optimism about the new oral GLP-1 medication, orforglipron, stating it could make treatment more accessible to underserved populations worldwide.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Liechtenstein | 1 | 8.00 | 0.05% | +0% | 38,137 | 18 | $6,900 | 3$ |
| Australia | 1 | 8.00 | 0.05% | +0% | 25,499,884 | 12,439 | $1,380,000 | 673$ |
| Totals | 2 | 25,538,021 | 12,457 | $1,386,900 | 676$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Australia:
Dr. Sean Wharton is the director of the Wharton Medical Clinic in Burlington, Ontario, who enrolled patients in Lilly’s study of orforglipron for obesity.
8
Liechtenstein:
Sean Wharton, director of the Wharton Medical Clinic in Burlington, expressed hope that a pill could potentially bring GLP-1 treatment to underserved populations worldwide.
8